Drug Therapies (AQA A-Level Psychology): Revision Notes
Drug Therapies
Drug therapy represents the primary biological treatment approach for schizophrenia, involving the use of medications to manage symptoms and improve patients' quality of life. While these medications do not cure schizophrenia, they effectively reduce symptom severity, enabling many individuals to function more normally in society.
Understanding drug therapy is crucial for comprehending how schizophrenia is managed medically. These treatments have transformed the lives of millions of patients worldwide since their introduction in the 1950s.
Understanding antipsychotic medications
Antipsychotic drugs form the cornerstone of schizophrenia treatment. These medications work by influencing brain chemistry, particularly neurotransmitter systems that become disrupted in schizophrenia. The first antipsychotic drug, chlorpromazine, was introduced in 1952 and revolutionised schizophrenia treatment by allowing many patients to live outside institutional care for the first time.
Antipsychotics are available in various forms including tablets, syrups, and injections, providing flexibility in treatment delivery. The medications are broadly categorised into two main types based on when they were developed and their specific effects on the brain.
The introduction of chlorpromazine marked a pivotal moment in psychiatric treatment, transforming schizophrenia from a condition requiring lifelong institutionalisation to one that could be managed in the community for many patients.
Types of antipsychotic drugs
Typical antipsychotics (first-generation)
Typical antipsychotics, also known as conventional antipsychotics, were the original medications developed in the 1950s. These drugs primarily target the brain's dopamine system by blocking dopamine receptors, particularly D2 receptors, which reduces the positive symptoms of schizophrenia such as hallucinations and delusions.
These medications work on the principle that schizophrenia involves excessive dopamine activity in certain brain regions. By blocking dopamine receptors, typical antipsychotics help restore more balanced brain chemistry. Symptoms like hallucinations typically diminish within days of treatment, while delusions may take several weeks to improve.
However, typical antipsychotics cause significant side effects related to movement and motor control. The most serious long-term consequence is tardive dyskinesia, a condition affecting approximately 15% of long-term users, causing involuntary muscle movements, particularly around the mouth and face. This condition can become permanent even after discontinuing the medication.
Atypical antipsychotics (second-generation)
Atypical antipsychotics emerged in the 1990s as an improvement over typical medications. These newer drugs, including clozapine, work differently by affecting multiple neurotransmitter systems, including serotonin and dopamine pathways. This broader mechanism of action allows them to address both positive and negative symptoms of schizophrenia more effectively.
The key advantage of atypical antipsychotics is their reduced risk of movement-related side effects compared to typical drugs. They cause significantly less tardive dyskinesia and fewer motor problems. Additionally, atypical antipsychotics show particular effectiveness in treating negative symptoms like reduced emotional expression and social withdrawal.
However, atypical antipsychotics introduce different side effects, including weight gain, increased diabetes risk, and neuroleptic malignant syndrome - a rare but potentially fatal condition involving fever, muscle rigidity, and cardiovascular problems. Some patients may also experience muscle tremors similar to Parkinson's disease symptoms.
Research evidence on drug effectiveness
Comparative effectiveness studies
Research Finding: Large-Scale Effectiveness Comparison
A comprehensive systematic review by Bagnall et al. (2003) analysed data from 171 controlled trials comparing typical and atypical antipsychotics. This large-scale analysis revealed that several atypical drugs, including risperidone, amisulpride, zotepine, olanzapine, and clozapine, demonstrated superior effectiveness compared to typical antipsychotics in reducing overall schizophrenia symptoms.
The study found that clozapine showed particular effectiveness in treating negative symptoms and helping treatment-resistant patients. Interestingly, quetiapine and sertindole performed no better than typical antipsychotics, highlighting that not all atypical drugs are equally effective.
Long-term treatment outcomes
Research Finding: Placebo Comparison Study
Davis et al. (1989) conducted a meta-analysis of over 100 studies comparing antipsychotics with placebos. Their findings demonstrated that approximately 70% of patients showed improvement after six weeks of antipsychotic treatment, compared to only 25% of those receiving placebo, confirming the genuine medical benefit of these medications.
Research Finding: Treatment Discontinuation Patterns
Lieberman et al. (2005) examined long-term treatment patterns in 1,432 individuals with chronic schizophrenia. They discovered that 74% of patients discontinued their medication within 18 months due to side effects or lack of effectiveness. Importantly, discontinuation rates were similar between typical and atypical drugs, though the reasons differed - atypical drugs were more often stopped due to metabolic side effects, while typical drugs were discontinued more frequently due to movement disorders.
Treatment effectiveness comparisons
Several studies have challenged the assumed superiority of atypical antipsychotics. Kahn et al. (2008) found that while antipsychotics remained effective for at least one year, atypical drugs were not necessarily more effective than typical ones for treating first-episode schizophrenia. This finding was supported by Stargardt et al. (2008), who analysed data from 3,121 patients and found no significant difference in relapse rates between drug types, though atypical drugs showed better outcomes in more severe cases.
Evaluation of drug therapies
Strengths of antipsychotic treatment
Drug therapy offers several important advantages for schizophrenia management. These medications are relatively inexpensive to produce and simple to administer, making them accessible treatments. Their effectiveness allows many patients to maintain relatively normal lives outside hospital settings - currently, fewer than 3% of people with schizophrenia in the UK require permanent hospitalisation.
The development of atypical antipsychotics has provided options for patients who experience severe side effects from typical drugs. These newer medications have expanded treatment possibilities and improved quality of life for many individuals who previously struggled with movement-related side effects.
Limitations and concerns
Despite their benefits, antipsychotic drugs face significant limitations. High discontinuation rates remain problematic, with approximately 40% of patients stopping treatment within the first year and 75% discontinuing within two years. This pattern typically occurs due to side effects or perceived lack of benefit, leading to symptom relapse.
Side effects continue to be a major concern. While atypical drugs reduce movement disorders, they introduce metabolic problems including weight gain, diabetes risk, and cardiovascular complications. Some patients develop serious neurological symptoms that can progress to coma or death.
The psychiatric community has raised concerns about the widespread promotion of antipsychotics being driven by pharmaceutical company profits rather than solely by patient benefit. The replacement of typical drugs with more expensive atypical alternatives has generated substantial financial gains for drug manufacturers, raising questions about treatment recommendations.
Additionally, many patients find that drug therapy alone is insufficient for complete recovery. The medications primarily address positive symptoms but may be less effective for negative symptoms and cognitive impairments, suggesting that combination approaches incorporating psychological therapies may be more beneficial for comprehensive treatment.
Key Points to Remember:
- Antipsychotic drugs are the main treatment for schizophrenia, working by blocking dopamine receptors to reduce positive symptoms like hallucinations and delusions
- Typical antipsychotics cause movement side effects including tardive dyskinesia, while atypical drugs cause metabolic side effects like weight gain and diabetes risk
- Research shows both drug types are effective, but neither is consistently superior across all symptoms and patient groups
- High discontinuation rates remain a major problem, with most patients stopping medication within two years due to side effects or perceived lack of benefit
- Drug therapy works best as part of comprehensive treatment that may include psychological interventions to address the full range of schizophrenia symptoms